<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03633227</url>
  </required_header>
  <id_info>
    <org_study_id>747-401</org_study_id>
    <nct_id>NCT03633227</nct_id>
  </id_info>
  <brief_title>Study of OCA Evaluating Pharmacokinetics and Safety in Patients With PBC and Hepatic Impairment</brief_title>
  <official_title>A Phase 4, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics and Safety of Obeticholic Acid in Patients With Primary Biliary Cholangitis and Moderate to Severe Hepatic Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intercept Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intercept Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 4, randomized, double-blind, placebo-controlled study will evaluate the PK and
      safety of OCA treatment in patients with primary biliary cholangitis (PBC) and moderate to
      severe hepatic impairment over a 48 week treatment period. Patients who have completed their
      48-week double blind treatment period will continue double-blind treatment until all
      randomized patients have completed their 48-week treatment period and the database for that
      period is locked. An open-label extension study in which all patients receive OCA will be
      considered following review of blinded safety and PK data.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate maximum concentration (Cmax) of OCA, its conjugates and total OCA (sum of OCA and its conjugates)</measure>
    <time_frame>Weeks 12, 18, 24, 30 and 48: 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours at</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate area under the concentration curve versus time curve from 0 to 24 hours (AUC 0-24) of OCA, its conjugates and total OCA</measure>
    <time_frame>24 hours at Day 1, and Weeks 12, 18, 24, 30, 36, and 48</time_frame>
    <description>Area under the concentration versus time curve from time 0 to 24 hours with measurable analyte concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate safety and tolerability as assessed by the incidence of treatment emergent adverse events and serious treatment emergent adverse events comparing OCA to placebo</measure>
    <time_frame>Baseline, Weeks 3, 6, 12, 18, 24, 30, 36, 42, 48, and every 3 months thereafter through approximately 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of OCA treatment compared to placebo on the model of end-stage liver disease (MELD) and its components</measure>
    <time_frame>Baseline, Weeks 3, 6, 12, 18, 24, 30, 36, 42, 48, and every 3 months thereafter through approximately 3 years</time_frame>
    <description>MELD Scores range from 6 [low risk] to 40 [high risk]. The three components of MELD (total bilirubin [mg/dL], serum creatinine[mg/dL], and INR) are input into the following equation to generate a MELD Score:
MELD = 3.78×ln[total bilirubin (mg/dL)] + 11.2×ln[INR] + 9.57×ln[serum creatinine (mg/dL)] + 6.43</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of OCA treatment compared to placebo on Child-Pugh score and its components</measure>
    <time_frame>At Day 1, and Weeks 6, 12, 18, 24, 30, 36, and 48</time_frame>
    <description>The 5 components of the Child Pugh Score are scored on a scale of 1-3 by increasing severity and then summed together to calculate the total score (range: 5 [compensated cirrhosis] - 15 [decompensated cirrhosis]). The components of the Child Pugh Score are total bilirubin [mg/dL], serum albumin [g/dL], INR, Ascites [none-severe], hepatic encephalopathy [none-grade 4]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of OCA treatment compared to placebo on total bilirubin (mg/dL) and direct bilirubin (mg/dL)</measure>
    <time_frame>Baseline, Weeks 3, 6, 12, 18, 24, 30, 36, 42, 48, and every 3 months thereafter through approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of OCA treatment compared to placebo on alkaline phosphatase (U/L), alanine aminotransferase (U/L), aspartate transaminase (U/L), and gamma glutamyl transaminase (U/L)</measure>
    <time_frame>Baseline, Weeks 3, 6, 12, 18, 24, 30, 36, 42, 48, and every 3 months thereafter through approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of OCA treatment compared to placebo on platelets (109/L)</measure>
    <time_frame>Baseline, Weeks 3, 6, 12, 18, 24, 30, 36, 42, 48, and every 3 months thereafter through approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of OCA treatment compared to placebo on fibroblast growth factor-19 (pg/mL)</measure>
    <time_frame>Baseline, Screening, Day 1, Weeks 3, 6, 12, 18, 24, 30, 36, 42, 48, and every 3 months thereafter through approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>. Evaluate the effect of OCA treatment compared to placebo on 7α hydroxy-4-cholesten-3-one (ng/mL)</measure>
    <time_frame>Baseline, Weeks 3, 6, 12, 18, 24, 30, 36, 42, 48, and every 3 months thereafter through approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of OCA treatment compared to placebo on plasma bile acids (µmol/L)</measure>
    <time_frame>Weeks 3, 6, 12, 18, 24, 30, 36, 42, 48, and every 3 months thereafter through approximately 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Liver Cirrhosis, Biliary</condition>
  <arm_group>
    <arm_group_label>Obeticholic Acid (OCA) 5 mg to 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obeticholic Acid (OCA)</intervention_name>
    <description>Moderate and Severe hepatic impairment classified as Child-Pugh Class B and C: 5 mg tablet of OCA once weekly titrating up to 5 mg OCA twice weekly based on tolerability at 3 months and subsequently titrating up to a maximum dose of 10 mg OCA twice weekly based on safety and tolerability for the duration of the study.</description>
    <arm_group_label>Obeticholic Acid (OCA) 5 mg to 10 mg</arm_group_label>
    <other_name>6alpha-ethylchenodeoxycholic acid (6-ECDCA)</other_name>
    <other_name>INT-747</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One tablet twice weekly (or a lower frequency based on safety and tolerability) for the duration of the study</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A definite or probable diagnosis of PBC (consistent with American Association for the
             Study of Liver Diseases [AASLD] and European Association for the Study of the Liver
             [EASL] Practice Guidelines [Lindor 2009, EASL 2009]), defined as having ≥2 of the
             following 3 diagnostic factors:

               -  History of elevated ALP levels for at least 6 months

               -  Positive antimitochondrial antibody (AMA) titer or if AMA negative or low titer
                  (≤1:80), PBC specific antibodies (anti-GP210 and/or anti-SP100) and/or antibodies
                  against the major M2 components (PDC-E2, 2-oxo-glutaric acid dehydrogenase
                  complex)

               -  Liver biopsy consistent with PBC (collected at any time prior to Screening)

          2. Evidence of cirrhosis including at least one of the following:

               -  Biopsy results consistent with PBC Stage 4

               -  Liver stiffness as assessed by Transient Elastography (TE) Median Value ≥16.9kPa

               -  Clinical evidence in the absence of acute liver failure consistent with cirrhosis
                  including: gastroesophageal varices, ascites, radiological evidence of cirrhosis
                  (nodular liver or enlargement of portal vein and splenomegaly)

               -  Combined low platelet count (&lt;140 000/mm3) with

                    -  persistent decrease in serum albumin, or

                    -  elevation in prothrombin time /INR (not due to antithrombotic agent use), or

                    -  elevated bilirubin (2× ULN)

          3. Satisfy the criteria of the modified CP classification for hepatic impairment during
             Screening:

               -  Moderate: CP-B (Scores 7 to 9) or

               -  Severe: CP-C (Scores 10 to 12)

          4. MELD score of 6 to 24 at Screening

          5. Taking UDCA for at least 12 months (stable dose for ≥3 months) prior to Day 1, or
             unable to tolerate or unresponsive to UDCA (no UDCA for ≥3 months)

        Exclusion Criteria:

          1. Non-cirrhotic or cirrhotic CP-A (Mild; Score 5 to 6)

          2. History of liver transplant or organ transplant

          3. History of alcohol or drug abuse within 12 months prior to Screening

          4. Hepatic encephalopathy (as defined by a West Haven score of ≥2 [AASLD, EASL 2014])

          5. History or presence of other concomitant liver diseases including:

               -  Hepatitis C virus infection and RNA positive

               -  Active hepatitis B infection; however, patients who have seroconverted (hepatitis
                  B surface antigen and hepatitis B e antigen negative) may be included in this
                  study after consultation with the medical monitor

               -  Primary sclerosing cholangitis

               -  Alcoholic liver disease

               -  Definite autoimmune liver disease or overlap hepatitis

               -  Gilbert's Syndrome

          6. In the opinion of the Investigator, fluctuating or rapidly deteriorating hepatic
             function prior to randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Weyer, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Intercept Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Judith Romano</last_name>
    <phone>+1(646) 757-2335</phone>
    <email>judith.romano@interceptpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Inland Empire Liver Foundation</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darlene Romo</last_name>
      <phone>909-883-2999</phone>
      <email>dromo@ieliverfoundation.com</email>
    </contact>
    <contact_backup>
      <last_name>Nazly Amaya</last_name>
      <phone>909-883-2999</phone>
      <email>namaya@ieliverfoundation.com</email>
    </contact_backup>
    <investigator>
      <last_name>Zeid Kayali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Ddavis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Ruiz</last_name>
      <phone>916-734-2911</phone>
      <email>mmruiz@ucdavis.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sandeep Dhaliwal</last_name>
      <phone>916-734-8696</phone>
      <email>sandhaiwal@ucdavis.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Christopher L. Bowlus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Schiff Center for Liver Diseases/ University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Elibero</last_name>
      <phone>305-243-6968</phone>
      <email>axe375@med.miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>Claudia Cottone</last_name>
      <phone>305-243-1104</phone>
      <email>cxc1335@med.miami.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Cynthia Levy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivia Tang</last_name>
      <phone>410-843-2069</phone>
      <email>otang@mdmercy.com</email>
    </contact>
    <contact_backup>
      <last_name>Sung Cho</last_name>
      <phone>410-576-5389</phone>
      <email>scho@mdmercy.com</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Thuluvath, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Wu</last_name>
      <email>elizwu@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Frederick Askari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kansas City Research Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Lynn</last_name>
      <phone>816-759-5274</phone>
      <email>llynn@kcresearchinstitute.com</email>
    </contact>
    <contact_backup>
      <last_name>Kelly Vargas</last_name>
      <phone>816-759-5274</phone>
      <email>kvargas@kcresearchinstitute.com</email>
    </contact_backup>
    <investigator>
      <last_name>Bradley Freilich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eden Shegena</last_name>
      <phone>614-366-5699</phone>
      <email>eden.shegena@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Caitlin Hayes</last_name>
      <phone>614-685-8814</phone>
      <email>caitlin.hayes@osumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Khalid Mumtaz, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Center for Liver Diseases</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Beth Luce</last_name>
      <phone>412-647-1461</phone>
      <email>lucem@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Dolores Esche</last_name>
      <phone>412-647-5422</phone>
      <email>Eschdm@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mordechai Rabinovitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Liver Institute at Methodist Dallas Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melba Townsend</last_name>
      <email>MelbaTownsend@mhd.com</email>
    </contact>
    <investigator>
      <last_name>Ashwini Mehta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine- Advanced Liver Therapies</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jana Lee</last_name>
      <phone>713-798-5382</phone>
      <email>janal@bcm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Catalina Gutierrez</last_name>
      <phone>713-798-5349</phone>
      <email>cataling@bcm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John M. Vierling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>American Research Corporation at theTexas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Forsyth</last_name>
      <phone>210-253-3426</phone>
      <email>nforsyth@txliver.com</email>
    </contact>
    <contact_backup>
      <last_name>Elisha Moreno</last_name>
      <phone>210-253-3426</phone>
      <email>emoreno@txliver.com</email>
    </contact_backup>
    <investigator>
      <last_name>Eric Lawitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Organ Transplant and Liver Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Cardona Gonzalez</last_name>
      <phone>206-215-2927</phone>
      <email>maria.cardonagonzalez@swedish.org</email>
    </contact>
    <contact_backup>
      <last_name>Allison Everett</last_name>
      <email>Allison.Everett@swedish.org</email>
    </contact_backup>
    <investigator>
      <last_name>Kris V. Kowdley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio Lucero</last_name>
    </contact>
    <investigator>
      <last_name>Alejandra Villamil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Austral</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Foa Torres</last_name>
      <email>MFOATORR@austral.edu.ar</email>
    </contact>
    <investigator>
      <last_name>Manuel Mendizabal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Aleman</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Colman</last_name>
      <email>ccolman@hospitalaleman.com</email>
    </contact>
    <investigator>
      <last_name>Maria Anders</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Britanico de Buenos Aires</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Delgado</last_name>
      <email>pdelgado@hbritanico.com.ar</email>
    </contact>
    <investigator>
      <last_name>Luis Colombato</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Gastroenterologia &quot;Dr Carlos Bonorino Udaondo&quot;</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aire</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalia Orellana</last_name>
    </contact>
    <investigator>
      <last_name>Mariano Cartier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Higea S.A.</name>
      <address>
        <city>Mendoza</city>
        <zip>M5500DPS</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Lopez</last_name>
      <email>laulopez1410@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Roberto Perez Ravier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Austral</name>
      <address>
        <city>Pilar</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariana Foa Torres</last_name>
    </contact>
    <investigator>
      <last_name>Manuel Mendizabal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Provincial del Centenario</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gariela Juaristi</last_name>
    </contact>
    <investigator>
      <last_name>Fernando Bessone</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerry Witton</last_name>
      <phone>(02) 9515 6006</phone>
      <email>kerry.witton@health.nsw.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Tatiana Tsoutsman</last_name>
      <phone>(02) 9519 7383</phone>
      <email>Tatiana.Tsoutsman@health.nsw.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Simone Strasser</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nepean Hospital</name>
      <address>
        <city>Kingswood</city>
        <zip>2747</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincenzo Fragomeli</last_name>
      <phone>(02) 4734 3466</phone>
      <email>Vincenzo.Fragomeli@health.nsw.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Gaaya Kanapathipillai</last_name>
      <phone>(02) 4734 2319</phone>
      <email>Gaaya.Kanapathipillai@health.nsw.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Martin David Weltman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CUB Hospital Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francoise Smits</last_name>
      <email>francoise.smits@erasme.ulb.ac.be</email>
    </contact>
    <contact_backup>
      <last_name>Nesrine Amari</last_name>
      <email>nesrine.amari@erasme.ulb.ac.be</email>
    </contact_backup>
    <investigator>
      <last_name>Christophe Moreno, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen UZA</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ansje Claesen</last_name>
    </contact>
    <investigator>
      <last_name>Sven Francque</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lili Schrijvers</last_name>
      <phone>32 16 34 16 18</phone>
      <email>liliane.schrijvers@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Natalie Van den Ende</last_name>
      <phone>32 16 34 07 49</phone>
      <email>natalie.vandenende@uzleuven.be</email>
    </contact_backup>
    <investigator>
      <last_name>Frederik Nevens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital das Clínicas da Universidade Federal de Minas Gerais - UFMG</name>
      <address>
        <city>Belo Horizonte</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefania Cotta Done</last_name>
      <email>stecotdon@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Claudia Couto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Rio Grande</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marisa Boff da Costa</last_name>
      <phone>55 51 3359 8749</phone>
    </contact>
    <investigator>
      <last_name>Mario Alvares-da-Silva</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <zip>054003-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christiane Omosako</last_name>
      <email>chris.sko08@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Suzane Ono</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Orlando Cerocchi</last_name>
    </contact>
    <investigator>
      <last_name>Aliya Gulamhusein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Tallinn Central Hospital</name>
      <address>
        <city>Tallinn</city>
        <zip>10617</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jelena Andrejeva</last_name>
      <email>andrejeva.jelena@keskhaigla.ee</email>
    </contact>
    <investigator>
      <last_name>Kulliki Suurmaa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Kull</last_name>
      <phone>37 253 318 685</phone>
    </contact>
    <investigator>
      <last_name>Riina Salupere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Leipzig AoR</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josephin Kister</last_name>
      <phone>49-341-97-24831</phone>
      <email>Josephin.Kister@medizin.uni-leipzig.de</email>
    </contact>
    <contact_backup>
      <last_name>Carolin Straube</last_name>
      <phone>49-341-97-12328</phone>
      <email>Carolin.Straube@medizin.uni-leipzig.de</email>
    </contact_backup>
    <investigator>
      <last_name>Johannes Tobias Martin Wiegand</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bekes Megyei Kozponti Korhaz Dr. Rethy Pal Tagkorhaz, 4. Belgyogyaszat-Gasztroenterologia-Hepatologia</name>
      <address>
        <city>Bekescsaba</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andera Opra</last_name>
    </contact>
    <investigator>
      <last_name>Marta Varga</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Socio Sanitaria Territoriale (ASST) di Monza</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Gemma</last_name>
      <phone>+39.039.233.2695</phone>
      <email>marta.gemma@unimib.it</email>
    </contact>
    <investigator>
      <last_name>Pietro Invernizzi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;UO. Medicina Metabolica Dipattimento di Scienze Biomediche, Metaboliche e Neuroscienze&quot;</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marzia Margotti</last_name>
    </contact>
    <investigator>
      <last_name>Pietro Andreone</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of Lithuanian University of Health Sciences Kauno Klinikos</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jurate Kondrackiene</last_name>
      <phone>0037068627982</phone>
    </contact>
    <investigator>
      <last_name>Limas Kupcinskas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klaipeda Seamen's Hospital</name>
      <address>
        <city>Klaipeda</city>
        <zip>LT-92288</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giedrius Simulionis, MD</last_name>
      <email>GSimulionis@jurlig.lt</email>
    </contact>
    <investigator>
      <last_name>Arturas Razbadauskas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital Santaros Klinikos</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ieva Sinkeviciute</last_name>
      <email>klinikiniai.tyrimai@santa.lt</email>
    </contact>
    <investigator>
      <last_name>Arida Buivydiene</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paseo Vall d`Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ibtissam Benabou</last_name>
      <phone>932746240</phone>
      <email>ibenabou@vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Victor Vargas Blasco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Mascort</last_name>
      <phone>34 955 012 065</phone>
      <phone_ext>31 20 65</phone_ext>
      <email>sara.mascort.exts@juntadeandalucia.es</email>
    </contact>
    <contact_backup>
      <last_name>Bianca Sanchez</last_name>
      <email>biancasb85@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Manuel Romero Gomez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari I Politecnic La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Hontangas</last_name>
      <phone>34961245856</phone>
      <email>vahonpla@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Marina Berenguer Haym</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ; American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology. 2009 Jul;50(1):291-308. doi: 10.1002/hep.22906.</citation>
    <PMID>19554543</PMID>
  </reference>
  <reference>
    <citation>European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009 Aug;51(2):237-67. doi: 10.1016/j.jhep.2009.04.009. Epub 2009 Jun 6.</citation>
    <PMID>19501929</PMID>
  </reference>
  <reference>
    <citation>Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, Weissenborn K, Wong P. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014 Aug;60(2):715-35. doi: 10.1002/hep.27210. Epub 2014 Jul 8.</citation>
    <PMID>25042402</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 8, 2018</study_first_submitted>
  <study_first_submitted_qc>August 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2018</study_first_posted>
  <last_update_submitted>May 29, 2020</last_update_submitted>
  <last_update_submitted_qc>May 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Biliary Cholangitis</keyword>
  <keyword>Primary Biliary Cirrhosis</keyword>
  <keyword>PBC</keyword>
  <keyword>Hepatic Impairment</keyword>
  <keyword>Cirrhosis</keyword>
  <keyword>Liver</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

